Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27802007 | 0.89 | MAP2K1 (0.57) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL1341039 | 0.85 | MAP2K1 (0.46) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL31401815 | 0.79 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL31401872 | 0.79 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL23673880 | 0.75 | MAP2K1 (0.56) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29425357 | 0.75 | MAP2K1 (0.56) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29781375 | 0.75 | MAP2K1 (0.56) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29781367 | 0.75 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL5992602 | 0.75 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29425445 | 0.75 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| EP-2121620-A1 | INHIBITORS OF MEK | Ardea Biosciences, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008089459-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-7160915-B2 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY, LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160915-B2 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY, LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160915-B2 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY, LLC (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1651214-A2 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026970-A1 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY | 2005-02-03 | — | — | US | disclosed |
| WO-2005009975-A2 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026970-A1 | N-methyl-substituted benzamidazoles | CYP3A5, CYP3A7, UGT2B7 | MAP2K1 4401/4885MAP2K2 4101/4885PIM1 1756/4885 |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | MAPK8, MAP3K8, MAP3K2 | MAP2K1 51/4885MAP2K2 38/4885PIM1 239/4885 |
| US-20100331334-A1 | INHIBITORS OF MEK | NRAS, BRAF, KSR2 | MAP2K1 54/4885MAP2K2 45/4885PIM1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.